Purpose of this Study
We are doing this study to evaluate the safety and effectiveness of a drug called isatuximab when it is used in
combination with lenalidomide and dexamethasone at lower doses. We want to know if this low dose combination can help patients with multiple myeloma achieve a better response while causing fewer or less severe side effects.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are newly diagnosed with multiple myeloma (NDMM); OR
- Are toxicity-vulnerable patients diagnosed with multiple myeloma
What is Involved?
Description
If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:
- Have a physical exam
- Have a bone survey (a series of x-rays of all the bones in the body)
- Have blood draws and give urine samples
- Have bone marrow samples taken
- Have images taken (X-rays, CT, MRI, or PET-CT scans)
- Have a tumor assessment
Study Details
Full Title
LCCC 1944, A Phase 2 Study of Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-Vulnerable Subjects with Newly Diagnosed Multiple Myeloma
Principal Investigator
Cristina
Gasparetto
Protocol Number
PRO00110204
NCT ID
NCT05145400
Phase
II
Enrollment Status
Open to Enrollment